InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Trading Down 2.9 %

Shares of NYSE NSPR opened at $2.39 on Friday. The company has a market capitalization of $59.46 million, a P/E ratio of -3.22 and a beta of 0.93. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The stock has a 50 day moving average of $2.59 and a 200-day moving average of $2.59.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD at the end of the most recent reporting period. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.